Opendata, web and dolomites

Glucoset

Boronic acid hydrogel sensor for intravascular (arterial) blood glucose monitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Glucoset project word cloud

Explore the words cloud of the Glucoset project. It provides you a very rough idea of what is the project "Glucoset" about.

least    optical    units    spontaneously    services    infusions    physicians    hydrogel    advantages    accuracy    turnover    accurate    convenient    addressable    consequently    episodes    exceeding    glycaemia    glucoset    thin    equally    dangerous    stay    introduction    2000    interference    catheters    patient    market    close    blood    central    glucose    980    size    million    micro    first    dome    sensibility    ill    icu    life    tip    solution    intravascular    shaped    monitoring    diseases    94    icus    sensor    levels    estimate    position    critical    estimates    risk    acute    fibres    patients    day    company    nurses    care    administration    frequently    population    savings    worldwide    critically    small    125    lives    unexpected    arterial    exposing    intensive    disturbing    caused    volume    length    time    drops    bed    venous    variability    wrist    installed    115    hypoglycaemic    style    demand    total    insulin    measuring    hyperglycaemia    continuous    1425    pass    direct    aging    pressure    incidents    needing   

Project "Glucoset" data sheet

The following table provides information about the project.

Coordinator
GLUCOSET AS 

Organization address
address: SLUPPENVEGEN 6
city: TRONDHEIM
postcode: 7037
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://www.glucoset.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLUCOSET AS NO (TRONDHEIM) coordinator 50˙000.00

Map

 Project objective

The problem: Blood glucose levels in critically ill patients require close attention by the physicians and nurses in the intensive care units (ICU) because these patients spontaneously develop hyperglycaemia and increased variability of blood glucose. Unexpected drops in blood glucose are frequently caused by over-administration of insulin – exposing patient´s lives to dangerous hypoglycaemic episodes. These incidents increase the length of stay in ICUs and each bed day in an ICU has large direct costs around €1425.

The solution: GlucoSet is a novel dome-shaped hydrogel sensor that changes its volume and consequently its optical path length in the presence of glucose. The hydrogel tip is built at the end of thin optical fibres (125 µm), which enables GlucoSet to be the only technology small enough to pass through wrist arterial catheters, installed in most (up to 94%) ICU patients, without disturbing the blood pressure monitoring. GlucoSet has the potential to be the first real-time monitoring system for measuring glycaemia from arterial blood, which offer several advantages over central venous access such as higher accuracy and sensibility, less risk of interference from infusions, and much more convenient use.

The market: Critical care services face increasing demand worldwide – more particularly in the EU. With continuous increase in aging population in Europe along with life style related diseases, the number of critically ill patients needing accurate glucose monitoring in the ICUs will certainly rise. GlucoSet AS estimates a total market size of € 980 million per year for the intravascular continuous glucose monitoring, being the company in a strong position to exploit an addressable turnover exceeding € 115 million, five years after market introduction. Equally important, we estimate that the GlucoSet will allow savings of at least €2000 per patient in ICUs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOSET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUCOSET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More  

STAR (2018)

Safe, Transparent, Active and Reliable mineral sunscreen technology

Read More